Abstract
Research into Alzheimer's disease (AD) pathology has identified several underlying disease processes that are potential targets for drug discovery and development. One strategy targets glutamatergic neurotransmission mediated by the N-methyl-D-aspartate (NMDA) receptor. Therapeutic intervention with high-affinity NMDA receptor antagonists, such as phencyclidine (PCP) and MK-801, is not practical due to adverse side effects; however, a low-moderate affinity, uncompetitive and strongly voltage-dependent NMDA receptor antagonist, memantine (NamendaTM), is well tolerated and recently has been approved by the U.S. Food and Drug Administration for the treatment of moderate to severe AD. Clinical results support NMDA receptor antagonism as a viable therapeutic strategy for AD and suggest that this novel pharmacologic approach, either alone or in combination with other drugs, is likely to significantly impact the current AD treatment paradigm.
Keywords
MemantinePhencyclidineNMDA receptorMedicineGlutamatergicPharmacologyDiseaseAdverse effectNeuroprotectionNeuroscienceAlzheimer's diseaseGlutamate receptorReceptorInternal medicineBiology
Affiliated Institutions
Related Publications
Amyloid-β/Fyn–Induced Synaptic, Network, and Cognitive Impairments Depend on Tau Levels in Multiple Mouse Models of Alzheimer's Disease
Alzheimer's disease (AD), the most common neurodegenerative disorder, is a growing public health problem and still lacks effective treatments. Recent evidence suggests that micr...
Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss
A molecular basis for memory failure in Alzheimer's disease (AD) has been recently hypothesized, in which a significant role is attributed to small, soluble oligomers of amyloid...
Publication Info
- Year
- 2004
- Type
- article
- Volume
- 59
- Issue
- 6
- Pages
- 22-7
- Citations
- 86
- Access
- Closed
External Links
Citation Metrics
86
OpenAlex
Cite This
Martin R. Farlow
(2004).
NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease..
PubMed
, 59
(6)
, 22-7.